Comparative Pharmacology
Head-to-head clinical analysis: BACLOFEN versus RELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACLOFEN versus RELA.
BACLOFEN vs RELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Adults: 250-350 mg orally 3-4 times daily.
None Documented
None Documented
Clinical Note
moderateBaclofen + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Baclofen is combined with Fluticasone propionate."
Clinical Note
moderateBaclofen + Clemastine
"The risk or severity of adverse effects can be increased when Baclofen is combined with Clemastine."
Clinical Note
moderateBaclofen + Venlafaxine
"The risk or severity of adverse effects can be increased when Baclofen is combined with Venlafaxine."
Clinical Note
moderateBaclofen + Nefazodone
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Terminal elimination half-life approximately 20–30 hours; prolonged in elderly and renal impairment
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
Primarily renal excretion of unchanged drug and metabolites; 70% to 80% eliminated via urine, remainder biliary/fecal
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The risk or severity of adverse effects can be increased when Baclofen is combined with Nefazodone."